Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Moderate Buy” from Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $39.83.

DAWN has been the topic of several research reports. JPMorgan Chase & Co. upped their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. Finally, The Goldman Sachs Group cut their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $16.64 on Wednesday. The business’s fifty day moving average price is $15.27 and its two-hundred day moving average price is $13.78. Day One Biopharmaceuticals has a fifty-two week low of $9.67 and a fifty-two week high of $17.85. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -6.99 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Research analysts expect that Day One Biopharmaceuticals will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total value of $322,200.00. Following the transaction, the insider now owns 1,224,662 shares of the company’s stock, valued at $19,729,304.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Jeremy Bender sold 7,615 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $116,128.75. Following the sale, the chief executive officer now owns 721,813 shares of the company’s stock, valued at $11,007,648.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Samuel C. Blackman sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total value of $322,200.00. Following the sale, the insider now directly owns 1,224,662 shares in the company, valued at approximately $19,729,304.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,781 shares of company stock valued at $883,160. 8.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. raised its position in shares of Day One Biopharmaceuticals by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after purchasing an additional 1,445 shares during the period. Fisher Asset Management LLC raised its position in shares of Day One Biopharmaceuticals by 89.0% during the fourth quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock worth $999,000 after purchasing an additional 32,238 shares during the period. Wellington Management Group LLP grew its holdings in shares of Day One Biopharmaceuticals by 77.7% during the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock worth $3,051,000 after buying an additional 91,393 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Day One Biopharmaceuticals by 28.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after buying an additional 472,654 shares in the last quarter. Finally, Quintet Private Bank Europe S.A. grew its holdings in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after buying an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.